|Bid||3.9800 x 3000|
|Ask||4.0200 x 1400|
|Day's Range||3.9100 - 4.1300|
|52 Week Range||1.3500 - 5.4200|
|Beta (3Y Monthly)||2.86|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 12, 2019 - Nov 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.78|
EDAP TMS S.A. (EDAP) has been upgraded to a Zacks Rank 1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Today we are going to look at EDAP TMS S.A. (NASDAQ:EDAP) to see whether it might be an attractive investment...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 28) Turning Point Therapeutics Inc (NASDAQ: TPTX ) Down ...
Third consecutive profitable quarter Positive reimbursement decision by the American Medical Association announced in June Significant improvement in gross profit margin from.
LYON, France, July 25, 2019 - EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced preliminary unaudited revenues for the second quarter ended June 30, 2019. Preliminary total revenue for the second quarter 2019 totaled EUR 12.5 million, a 45% year-over-year increase. Growth in total revenue includes strong 98% growth in HIFU sales, which totaled EUR 4.6 million for the second quarter.
EDAP TMS SA (EDAP) (“the Company”), the global leader in therapeutic ultrasound, today announced that the American Medical Association’s (“AMA”) CPT® Editorial Panel, at its May 2019 meeting, accepted EDAP’s application to establish a new Category 1 CPT code that will facilitate reimbursement for the ablation of malignant prostate tissue with HIFU technology. The CPT code description selected by the Panel is “Ablation of malignant prostate tissue, transrectal, with high intensity focused ultrasound (HIFU) including ultrasound guidance.” The code will be included in the next CPT® Codebook and be effective on January 1, 2021.
EDAP Reports 2019 First Quarter Results HIFU revenue growth of 58.6% year-over-yearProfitable for second consecutive quarter Total Q1 revenues of EUR 10.1 million;.
is expected to report earnings of 2 cents a share on sales of $14.4 million after the market closes on on May. 15, based on a FactSet survey of two analysts. The company's American depository receipts have risen 49.5% since the company last reported earnings on Apr. 1. Quarterly estimates have fallen less than 1 cent a share in the past month.
Company to host conference call and webcast on Thursday, May 16, at 8:30 am EDT LYON, France, May 2, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic.
LYON, France, April 29, 2019 -- EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, announced today that it will demonstrate the capabilities of its range of minimally-invasive therapeutic ultrasound products, including its breakthrough Focal One® HIFU (High Intensity Focused Ultrasound) advanced robotic technology for the targeted ablation of prostate tissue, at booth #2211 at the American Urology Association ("AUA") Annual Meeting, which is being held May 3-6, 2019, at Mc Cornick Place, in Chicago, IL. This will be the first time that EDAP is showcasing Focal One at AUA.
Unfortunately, investing is risky - companies can and do go bankrupt. On the other hand, if you find a high quality business to buy (at the right price) you can more than double your money! Take, for example EDAP TMS S.A. (NA...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 1) Abbott Laboratories (NYSE: ABT ) AEterna Zentaris Inc. ...
NEW YORK, NY / ACCESSWIRE / April 2, 2019 / EDAP TMS SA Sponsored ADR (NASDAQ: EDAP ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on April 2, 2019 at 8:30 ...
Reports record revenues for the fifth consecutive year Record fiscal year 2018 revenues of €39.2 million Q4 2018 HIFU net sales increased 79% year-over-year Profitable.
April 1, 2019 - EDAP TMS SA (EDAP), the global leader in therapeutic ultrasound, today announced that the University of Chicago Medicine became the first medical center in the Midwest to offer focal therapy to men with localized prostate cancer, using Focal One, the only advanced robotic ultrasound technology available to target and ablate diseased prostate tissue. UChicago Medicine is the fifth medical center in the U.S. to acquire Focal One since the new system for prostate tissue ablation received 510(k) clearance from the FDA in June 2018.
Company to host conference call and webcast on Tuesday, April 2 at 8:30am EDT LYON, France, March 21, 2019 - EDAP TMS SA (Nasdaq: EDAP), the global leader in therapeutic.
Houston Methodist Hospital initially invested in EDAP's first generation HIFU system, Ablatherm, in early 2016, and within two years of positive experience made the decision to invest in the next generation Focal One device. This confirms the benefits of EDAP's innovative HIFU technology not only for patients, but also in terms of hospital financials. Based on a solid business case built upon Ablatherm's usage, the Hospital showed a rapid return on investment, resulting in the acquisition of Focal One.
EDAP TMS SA (EDAP) ("the Company"), the global leader in therapeutic ultrasound, today announced that UCI Health (UCI) has become the first medical center in the United States to treat prostate cancer patients with Focal One, the world's most advanced high intensity focused ultrasound (HIFU) technology. UCI is one of the three medical centers in the country to acquire Focal One, which provides urologists with one of the most precise tools on the market for the targeted, non-invasive ablation of prostate cancer tissue.
The big shareholder groups in EDAP TMS S.A. (NASDAQ:EDAP) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own Read More...
January 18, 2019 - EDAP TMS SA (EDAP) today announced that Brooklyn, New York's Maimonides Medical Center has become the second hospital in the United States, and the first on the East Coast, to acquire the groundbreaking Focal One high intensity focused ultrasound (HIFU) technology, the world's most advanced non-invasive prostate ablation device. Maimonides Medical Center urologists were recently trained on the use of Focal One and will begin to schedule the outpatient treatments for eligible patients with localized prostate cancer in February 2019.
EDAP TMS SA (EDAP) ("the Company"), the global leader in therapeutic ultrasound, announced today that the Company has completed sales of two additional Focal One High Intensity Focused Ultrasound (HIFU) devices to two leading hospitals in Brazil: Hospital 9 de Julho and Hospital Moriah. With these sales, EDAP has now sold five Focal One HIFU devices into the Brazil market to date.